Ingested IFN-α has biological effects in humans with relapsing-remitting multiple sclerosis

Multiple Sclerosis

Volumn 3, Issue 1, 1997, Pages 1-7

  Brod, Staley A ^a   Kerman, Ronald H ^b   Nelson, Laura D ^a   Marshall Jr , Gailen D ^a   Henninger, Evelyn M ^a   Khan, Mohammed ^a   Jin, Rui ^a   Wolinsky, Jerry S ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Gut associated lymphoid tissue (GALT); IFN ; IFN ; Multiple sclerosis; Oral administration

Indexed keywords

ALPHA INTERFERON; ANTIBODY; BIOLOGICAL RESPONSE MODIFIER; CONCANAVALIN A; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 2; RECOMBINANT ALPHA2A INTERFERON; TRANSFORMING GROWTH FACTOR BETA;

ANTIBODY PRODUCTION; ARTICLE; BLOOD LEVEL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DOSE RESPONSE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MULTIPLE SCLEROSIS; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; RELAPSE; T LYMPHOCYTE;

EID: 0030946161     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859700300101     Document Type: Article

References (45)

1. Isaacs A, Lindemann J. (1957) Virus Interference I. The interferon. Proc R Soc Lond (Biol) 147: 258-367.
2. Dron M, Tovey MG. (1992). Interferon α/β, gene structure and regulation. In S. Baron et al Interferon - Principles and Medical Applications. (ed.) UTMB Press: Galveston, TX pp 33-46.
3. Uze G, Lutfalla G, Knudson KE. (1995) α and β Interferons and their receptor and their friends and relations. J Interferon Cyt Res 15: 3-26.
4. Balkwill FR. (1985) The regulatory role of interferons in the human immune response. In Taylor-Papadimitriou J Interferons: Their impact in biology of medicine (ed.) Oxford Medical Publications: Oxford UK. pp 61-80.
5. Wolinsky J. (1993) Multiple Sclerosis. Current Neurology, (ed.) S Appel, vol. 13. Mosby-Year Book, Inc: New York. pp 167-207.
6. Antel JP, Freedman MS, Brodsovsky S, Francis GS, Duquette P. (1989) Activated suppressor cell function in severely disabled patients with multiple sclerosis. Ann Neurol 25: 204-207.
7. MS Group. (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 662-667.
8. Durelli L, Bongioanni MR, Cavallo R, Ferraro B, Ferri R, Ferrio MF, Bradac GB, Riva A, Vai S, Geuna M, Bergnami L, Bergamasco B. (1994) Chronic systemic high-dose recombinant Interferon alpha-2a reduces exacerbation rate, MRI signs of activity, and lymphocyte Interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 44: 406-413.
9. MS Group. (1995) Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 45: 1277-1285.
10. 1b (Betaseron®) treatment of relapsing-remitting multiple sclerosis decreases CD3-mediatcd TNF-α and increases CD3-mediated IL-6 production in vitro. Neurology 46: 1633-1638.
11. MS Group. (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years. Neurology 47: 889-894.
12. Alvord EC, Shaw CM, Huby S, Kies MK. (1965) Encephalitogen-induced inhibition of experimental allergic encephalomyelitis: prevention, suppression, and therapy. Ann NY Acad Sci 122: 333-345.
13. Brod SA, Burns DH. (1994) Suppression of relapsing experimental allergic encephalomyelitis in the SJL/J mouse by oral administration of type I interferons. Neurology 44: 1144-1148.
14. Brod SA, Khan M, Pappolla M. (1995) Oral administration of human or murine IFN-α suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis. J Neuroimmunol 58: 61-69.
15. Brod S, Khan M. (1996) Oral administration of murine IFN-α is more effective than parenteral administration in the suppression of relapses in EAE. J Autoimmunity 9: 11-20.
16. Hartung H-P, Michels M, Reiners K, Seeldreyers P, Archelos P, Toyka K. (1993) Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis. Neurology 43: 2331-2335.
17. Poser CM, Paty DW, Scheinberg L, MacDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberborg DH, Tourtellotte WW. (1983) New diagnostic criteria for multiple sclerosis. Ann Neurol 13: 227-231.
18. Young AS, Cummins JM. (1990) The history of Interferon and its use in animal therapy. E African Med J 67: (suppl 2), SS31-63.
19. Kerman R, Floyd M, Buren CV, Kahan B. (1980) Improved allograft survival of strong immune responder-high risk recipient with adjuvant ATG therapy. Transplantation 30: 450-454.
20. Rieckmann P, Martin S, Weichselbraun I, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Luer W, Helwig A, Poser S. (1994) Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse. Neurology 44: 2367-2372.
21. Cher DJ, Mosmann TR. (1987) Two types of murine helper T cells. II. Delayed-type hypersensitivity is mediated by Th1 clones. J Immunol 138: 3688-3694.
22. Boom WH, Liano D, Abbas AK. (1988) Heterogeneity of helper/inducer T lymphocytes. II. Effects of interleukin-4 and interleukin-2 producing T cells clones on resting B cells. J Exp Med 167: 1350-1363.
23. Kim J, Woods A, Becker-Dunn E, Bottomly K. (1985) Distinct functional phenotypes of cloned Ia-restricted helper T cells. J Exp Med 162: 188-201.
24. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. (1986) Two types of murine helper T cell. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348-2354.
25. Waksman B, Reynolds WE. (1984) Multiple sclerosis as a disease of immune regulation. Proc Soc Exp Biol Med 175: 282-294.
26. Ding L, Shevach E. (1992) IL-10 inhibits mitogen induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol 148: 3313-3139.
27. Malefyt R, Haanen J, Spits H, Roncarolo M-G, te Velde A, Figdor C, de Vries J. (1991) IL-10 and viral IL-10- strongly reduce antigen specific human T cell proliferation by diminishing the antigen presenting capacity of monocytes via downregulation of class II MHC expression. J Exp Med 174: 915-924.
28. Brod SA, Benjamin D, Hafler DA. (1991) Restricted T cell expression of IL-2/IFN-γ mRNA in human inflammatory disease. J Immunol 147: 810-815.
29. Benvenuto R, Paroli M, Buttinelli C, Franco A, Barnaba V, Fieschi C, Balsano F. (1992) TNF-α and IFN-γ synthesis by CSF derived T cell clones in MS. Ann NY Acad Sci 650: 341-346.
30. Chofflon M, Juilliard C, Juilliard P, Gauthier G, Grau GE. (1992) TNF-α production as a possible predictor of relapse in patients with MS. Eur Cytokine Netw 3: 523-531.
31. Olsson T. (1992) Cytokines in neuroinflammatory disease: role of myelin reactive T cell production of IFN-γ. J Neuroimmunol 40: 211-218.
32. Perrella O, Carrieri PB, de Mercato R, Buscaino GA. (1993) Markers of activated T lymphocytes and T cell receptor gamma/delta+ in patients with MS. Eur Neurol 32: 152-155.
33. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. (1988) Increased production of IFN-γ and TNF precedes clinical manifestations in MS: do cytokines trigger off exacerbations?. Acta Neurol Scand 78: 318-323.
34. Noronha A, Richman DP, Arnason BGW. (1985) Multiple Sclerosis: Activated cells in the cerebrospinal fluid in acute exacerbations. Ann Neurol 18: 722-725.
35. Correale J, Gilmore W, Li S, McMillan M, McCarthy K, Le T, Weiner LP. (1995) Patterns of cytokine secretion by autoreactive PLP-specific T cell clones during the course of multiple sclerosis. J Immunol 154: 2959-2968.
36. Brod SA, Khan M, Bright J, Sriram S, Marshall GD, Henninger EM, Kerman RH, Wolinsky JS. (1995) Decreased CD3-mediated IFN-γ production in relapsing-remitting multiple sclerosis. Ann Neurol 37: 546-549.
37. Mosmann TR, Moore K. (1991) The role of IL-10 in cross-regulation of Th1 and Th2 responses. Immunol Today 12: no. 3, A49-53.
38. Link J, Fredrickson S, Soderstrom M, Olsson T, Hojeberg B, Ljungdahl A, Link H. (1994) Organ specific autoantigens induce TGF-β mRNA expression in mononuclear cells in MS and MG. Ann Neurol 35: 197-203.
39. Moore K, O'Garra A, de Waal Malefyt R, Vieira RP, Mosmann T. (1993) Interleukin 10. Annu Rev Immunol 11: 165-190.
40. Jinquan T, Larsen CG, Gesser B, Matsushima K, Thestrup-Pedersen K. (1993) Human IL-10 is a chemoattractant for CD8+ T lymphocytes and an inhibitor of IL-8-induced CD4+ T lymphocyte migration. J Immunol 151: 4545-4551.
41. Horisberger MA. (1992) Mx protein: Function and mechanism of acton. In S. Baron et al. Interferon: Principles and medical applications (ed.) UT Press: Galveston, TX. pp 215-224.
42. ser. J Interferon Res 12: 411-413.
43. Blalock JE, Baron S, Johnson HM, Stanton GJ. (1982) Transmission of interferon-induced activities by cell to cell communication. Texas Reports on Biology and Medicine 41: 344-349.
44. ser. J Interferon Res 9: suppl. 1, S51-60.
45. Smith ME, Stone LA, Albert PS, Frank JA, Martin R, Armstrong M, Maloni H, McFarlin DE, McFarland HF. (1993) Clinical worsening in MS is associated with increased frequency and area of gadopentate dimeglumine-enhancing MRI lesions. Ann Neurol 33: 480-489.